Tech Company Financing Transactions
Romark Laboratories Funding Round
Romark Laboratories, operating out of Tampa, secured $18 million from D. E. Shaw Group.
Transaction Overview
Company Name
Announced On
12/21/2007
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds from this financing will enable Romark to advance development of its lead compound, nitazoxanide, for the treatment of hepatitis C, and advance its next-generation thiazolide drug candidates for the treatment of hepatitis B and C and other viral diseases. Romark is currently conducting a U.S. Phase 2 trial of nitazoxanide in hepatitis C patients who have failed standard treatments, and expects to begin a U.S. Phase 2 trial in treatment naïve patients in the first quarter of 2008.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3000 Bayport Dr. 200
Tampa, FL 33607
USA
Tampa, FL 33607
USA
Phone
Website
Email Address
Overview
Romark Laboratories is a biotechnology company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases, cancers, and autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Ayers
Chief Financial Officer
Kevin Cowley
Chief Operating Officer
Jean-François Rossignol
Chief Scientific Officer
Celine Rossignol
VP - Operations
Ricardo Zayas
Browse more venture capital transactions:
Prev: 12/20/2007: Acquia venture capital transaction
Next: 12/21/2007: Kyte.tv venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs